Letter Regarding "Revolutionizing NSCLC Treatment: Unleashing the Potential of IBI351 and Its Critical Care Impact"

J Thorac Oncol. 2025 Jan;20(1):e17-e18. doi: 10.1016/j.jtho.2024.10.020.

Authors

Chongrui Xu¹, Jia-Xin Lin¹, Qing Zhou¹, Yi-Long Wu²

Affiliations

¹ Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
² Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China. Electronic address: [email protected].

PMID: 39794112
DOI: 10.1016/j.jtho.2024.10.020

No abstract available

Publication types

Letter